Evaxion Biotech A/S a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, has now finalized recruitment for Phase 1/2a clinical trial of EVX-02 in adjuvant melanoma patients.
The Company already conducts the successful EVX-01 program with clinical testing in Australia, Europe and the US, where app. 100 patients suffering from malignant melanoma (metastasized skin cancer) will be treated with EVX-01 therapy in combination with Keytruda® from Merck. In the EVX-02 program, Evaxion treats patients with adjuvant melanoma, meaning that their tumors have been successfully removed (surgically), and in the study the focus of the therapy is to avoid relapse.
Recommended AI News: Spark Sport Joins Hands With Amagi to Deliver Outstanding Live Experiences
In the EVX-02 study encouraging preliminary findings around its potential clinical benefit now allows Evaxion to accelerate the development program. Following the finalization of recruitment, Evaxion will advance into a dedicated Phase 2b clinical trial using its patented DNA-based immunotherapy.
For the patients enrolled in the Phase 1/2a clinical trial, Evaxion’s proprietary PIONEER™ AI technology identified a sufficient number of mutations to design a personalized treatment and so far, no serious side effects have been reported.
Lars Wegner, CEO of Evaxion, said:
“Completion of recruitment for the Phase 1/2a clinical trial of EVX-02 is an important milestone, which supports our belief that the Evaxion approach is feasible. EVX-02 appears to be well tolerated and shows encouraging signs as a treatment for adjuvant melanoma patients. The T-cell activation is promising, which allows us to take data and insights from this clinical trial and move into a dedicated Phase 2 clinical trial.”
Recommended AI News: Dawson Racing and LEXIT Announce Partnership for NFTs
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.